@isabellemahe.bsky.social
How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! @RPTHjournal doi.org/10.1016/j.rp...
Extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose in patients with active cancer and #cvVTE, based on findings from the API-CAT trial presented at #ACC25. Read the journal scan to learn more: bit.ly/43w2A8v #CardioSky #MedSky
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK #ACC25 | @accintouch.bsky.social
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary: nej.md/41YkRZK #MedSky
#API-CAT study by the #nejm.org. #accintouch.bsky.social #isth.org #apixaban #VTE #cancer
NEJM.org@nejm.org · last yr.Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.
Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT Trial) | NEJM
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months...
youtu.be
#API-CAT study by the @nejm.org. @accintouch.bsky.social @isth.org #apixaban #VTE #cancer
NEJM.org@nejm.org · last yr.In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary: nej.md/41YkRZK #MedSky
#APICAT trial at #ACC25 #LBCT #cardioonc 🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE 🩸more than half female! 👏🏽👏🏽 🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed 🩸no increase in deaths
Une étude majeure dans la prise en charge des patients atteints de cancer et traités pour un événement thromboembolique veineux, deuxième cause de décès, a été menée et coordonnée par la Pr Isabelle Mahé, cheffe du service de médecine interne de @hoplouismourier.bsky.social A découvrir ici 👇
Assistance Publique – Hôpitaux de Paris (AP-HP)@ap-hp.bsky.social · last yr.🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire Découvrez les résultats 👉 swll.to/sOSmEZC
🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire Découvrez les résultats 👉 swll.to/sOSmEZC
@acc25.bsky.social Isabelle Mahe presents API-CAT Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!
Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE #ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
Finally! More data to add to the EVE trial APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%) #Hemesky #BSH www.nejm.org/doi/full/10....
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | NEJM
In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and dec...
nejm.org
@acc2025.bsky.social @jaccjournals.bsky.social
@isabellemahe.bsky.social · last yr.The article published in the @NEJM.org can be accessed.see below Citation: Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
The article published in the @NEJM.org can be accessed.see below Citation: Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
JACC Journals@jaccjournals.bsky.social · last yr.Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE #ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients www.nejm.org/doi/full/10....
Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say? Our latest review breaks down the data, limitations, and next steps. @davidmsmadja.bsky.social @isabellemahe.bsky.social 📑 Read now: buff.ly/4ijJQNq
The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive @DavidMSmadja @RPTHjournal doi.org/10.1016/j.rp...
